Duration
12 weeks
Cost
Free to Patients
Phase
Phase III
Closes
Apr 2027
A Phase 3 study evaluating XEN1101 added to existing anti-seizure medications in adults with primary generalized tonic-clonic seizures. Study medication is provided at no cost.
Only 0 spots remaining
Apply soon to secure your place.
Trial Summary
Xenon Pharmaceuticals
Phase III, Randomized, Double-Blind, Placebo-Controlled Study evaluating the safety, tolerability, and efficacy of XEN1101 as adjunctive therapy in focal-onset seizures.